株式会社極東書店
🔍
ログイン 会員登録

株式会社極東書店トップ ＞ 商品一覧 ＞ Antiangiogenic Cancer Therapy.

商品詳細

Antiangiogenic Cancer Therapy.

Antiangiogenic Cancer Therapy.

・ISBN 978-0-367-38881-2 paper GB£ 70.99

￥22,489.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り ★★★

カートに入れる

電子版あり 大学・学術機関向け電子ブック（eBook）ISBN 9780429122200

電子ブックの価格を見る

著者・編者Davis, Darren W. / Herbst, Roy S. / Abbruzzese, James L. (eds.),
出版社 (CRC Press, UK)
出版年月2019
ページ数876 pp.
言語ENG
ニュース番号＜A01-4985＞

解説

Top Investigators Explore the Complexities of Angiogenesis Cancer Research

The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.

Compiles the results of four decades of progress

Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject.

  • Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.
  • Covers specific molecular targets for inhibiting angiogenesis in cancer therapy.
  • Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors.
  • Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.

    • This volume celebrates progress made in four decades, and more importantly, it provi